SLEIS 2026 will examine Sri Lanka's Health Economy at a summit on 12-13 October 2026, with the session 'Reimagining Healthcare for a Modern Health Economy' featuring executives from Hemas and Sunshine and moderated by Sunshine's CEO; sponsors include Dialog and Hayleys. Registrations are open.
Diversified Holdings · Industrial Conglomerates
Hemas Holdings PLC is a diversified Sri Lankan conglomerate with principal activities across consumer goods, healthcare, mobility, leisure, travel and aviation, and logistics and maritime services.
HHL shares are down 6.1% over the past year and last closed at Rs 31.00 on Sep 30, 2026.
Monthly seasonality
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.3 | -2.3 | -12.4 | +11.1 | -2.7 | +3.1 | -3.0 | -0.9 | -2.2 | +0.0 | +0.0 | +0.0 |
| 2025 | +10.7 | +3.7 | +1.3 | +1.2 | +15.2 | +8.9 | +1.0 | -1.3 | +7.6 | +6.1 | +3.2 | -3.6 |
| 2024 | +0.1 | +8.0 | +7.8 | +10.0 | -1.5 | -4.0 | -5.4 | -5.7 | +4.8 | +6.9 | +1.7 | +21.6 |
| 2023 | +5.0 | +8.0 | +2.0 | -2.8 | +0.5 | +9.4 | +10.5 | +5.5 | -1.9 | -10.2 | -0.6 | -3.0 |
| 2022 | +4.9 | -8.7 | -29.6 | -7.6 | +8.2 | -2.2 | +5.7 | +22.6 | +11.4 | -13.4 | +1.8 | +0.4 |
| 2021 | -3.1 | -16.4 | +1.9 | -3.0 | -0.1 | +2.5 | -3.5 | -7.6 | -2.7 | +3.2 | -6.5 | -2.6 |
| 2020 | -10.2 | -6.7 | -15.1 | +0.0 | +0.0 | +2.4 | -6.0 | +0.5 | +25.0 | -7.6 | +27.0 | +13.6 |
| 2019 | -4.5 | -4.7 | -4.0 | -4.0 | -5.6 | -8.8 | +25.0 | -3.2 | +0.0 | +6.8 | +3.0 | +0.6 |
| 2018 | -4.8 | +4.3 | +0.0 | +0.0 | -0.8 | -9.6 | -10.8 | -8.0 | -7.1 | -0.6 | +4.7 | +0.0 |
| 2017 | +2.0 | +6.9 | +1.7 | +7.5 | +3.8 | +25.6 | -4.5 | -11.6 | -8.4 | +9.2 | -3.8 | +0.8 |
| 2016 | -8.5 | -6.0 | +0.1 | +13.7 | -0.1 | -5.4 | +4.0 | +7.4 | +8.3 | +2.9 | -11.2 | +4.2 |
| 2015 | +10.4 | -2.6 | -6.8 | +2.6 | +5.4 | +1.9 | +7.4 | -0.1 | -3.4 | -2.9 | +3.0 | +9.3 |
| 2014 | +23.5 | -8.3 | -2.1 | +12.5 | -3.3 | +6.8 | +12.1 | +3.9 | +19.6 | +14.8 | -2.9 | +9.3 |
| 2013 | +3.7 | -5.0 | +1.5 | +6.7 | +28.1 | -6.5 | -4.9 | -8.5 | +6.7 | +1.6 | +2.2 | +2.4 |
| 2012 | +0.0 | +0.0 | +0.0 | -8.4 | -12.4 | +4.7 | +0.0 | +11.8 | +23.5 | -8.2 | -3.6 | +0.0 |
| Average | +2.1 | -2.1 | -3.8 | +2.8 | +2.5 | +1.9 | +1.8 | +0.3 | +5.4 | +0.6 | +1.3 | +3.8 |
| ASPI average | +3.1 | -2.7 | -4.7 | +2.0 | +0.2 | +0.8 | +3.1 | +2.2 | +3.2 | -0.1 | +1.0 | +3.0 |
| Median | +1.2 | -3.6 | +0.1 | +1.9 | -0.1 | +2.4 | +0.0 | -0.9 | +4.8 | +2.2 | +1.7 | +0.7 |
| % up | 64% | 36% | 50% | 57% | 43% | 60% | 47% | 40% | 53% | 57% | 57% | 64% |
Fundamentals
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | Rs 127.4B +8.0% | Rs 118.0B -3.0% | Rs 121.6B +6.7% | Rs 113.9B +44.5% | Rs 78.8B +22.2% | Rs 64.5B +4.7% | Rs 61.6B -3.8% | Rs 64.1B +26.0% |
| Operating profit | Rs 14.1B +3.2% | Rs 13.7B +15.0% | Rs 11.9B +8.7% | Rs 11.0B +61.6% | Rs 6.8B +11.9% | Rs 6.1B +70.2% | Rs 3.6B -37.1% | Rs 5.7B +33.4% |
| Net profit | Rs 9.3B +11.4% | Rs 8.3B +31.2% | Rs 6.4B +25.4% | Rs 5.1B +4.8% | Rs 4.8B +44.7% | Rs 3.3B +145.3% | Rs 1.4B -63.0% | Rs 3.7B +24.7% |
| EPS | 2.98 +10.4% | 2.70 -73.6% | 10.24 +43.0% | 7.16 +0.6% | 7.12 +30.4% | 5.46 +163.8% | 2.07 -63.4% | 5.65 +20.7% |
Compared with the same period a year earlier.
Per-share figures are as reported, not adjusted for splits.
Recent dividends
- 2026 · finalRs 0.75
- 2026 · first interimRs 0.25
- 2025 · finalRs 0.70
- 2025 · first interimRs 1.00
- 2024 · finalRs 3.00
- 2024 · first interimRs 0.40
- 2023 · finalRs 1.95
- 2023 · first interimRs 0.40
| # | Company | Price | Mkt cap | P/E | P/B | EPS | ROE | Div Yield |
|---|---|---|---|---|---|---|---|---|
| 1 | JKH.N0000 | 18.70 | Rs 331.8B | 22.7 | 0.80 | 0.82 | 3.49% | 1.60% |
| 2 | MELS.N0000 | 185.00 | Rs 215.6B | 10.7 | 1.29 | 17.34 | 12.13% | 4.41% |
| 3 | HAYL.N0000 | 225.50 | Rs 179.3B | 12.1 | 1.52 | 18.71 | 13.67% | 2.66% |
| 4 | CARS.N0000 | 720.00 | Rs 141.4B | 15.5 | 1.29 | 46.35 | 8.68% | 1.76% |
| 5 | CTHR.N0000 | 540.00 | Rs 108.8B | 13.9 | 2.91 | 38.92 | 20.99% | 2.82% |
| 6 | VONE.N0000 | 88.80 | Rs 101.1B | 7.2 | 0.81 | 12.27 | 11.20% | 1.69% |
| 7 | HHL.N0000 · this company | 31.00 | Rs 92.9B | 10.7 | 1.66 | 2.89 | 15.53% | 3.23% |
| 8 | BUKI.N0000 | 846.00 | Rs 86.3B | 19.4 | 1.09 | 43.50 | 6.34% | 2.38% |
| Peer median · 7 companies | - | - | 13.9 | 1.29 | - | - | 2.38% |
About Hemas Holdings Ltd.
Hemas Holdings PLC is a diversified Sri Lankan conglomerate with principal activities across consumer goods, healthcare, mobility, leisure, travel and aviation, and logistics and maritime services. The Group markets home and personal care and other consumer products domestically and in regional markets, and has a portfolio of businesses across pharmaceuticals, hospitals, hospitality and travel. The Healthcare vertical comprises pharmaceutical distribution and manufacturing (Morison), and a hospitals group operating facilities such as Wattala and Thalawathugoda; the Consumer vertical includes home and personal care categories and brands such as Atlas (including a 'Back to School' range). The Group also operates hotels and inbound travel businesses including Serendib Hotels (SHOT) and Anantara Peace Haven Tangalle, and maintains operations in Sri Lanka with regional presence in Bangladesh, West Bengal and Myanmar. Hemas positions itself as a national leader in consumer and healthcare solutions, seeking to develop brands, commercial partnerships and manufacturing capacity while engaging in route-to-market and regulatory initiatives relevant to its sectors.
AI analysis
bullishEvidence points bullish: earnings grew in FY2026 and Hemas has a net-cash balance sheet, supporting a moderately undervalued rating. The June quarter's profit fell 15.7% as margins compressed.
Read the full report (Sep 24, 2026) →News sentiment
Describes news flow, not a forecastHigher than 0% of its last 19 months · 5 of 9 in its sector
6 articles in 30 days: 1 positive, 4 negative, 1 neutral.
The Sri Lanka Economic & Investment Summit 2026 will feature a session 'Reimagining Healthcare for a Modern Health Economy' on Oct 12-13 to explore private-sector investment and opportunities across healthcare services, pharmaceuticals and medical technology. Panelists include Hemas Holdings (HHL.N0000) and Sunshine Holdings (SUN.N0000).
Colombo Stock Exchange opened higher as the ASPI rose 30.69 points to 21,068.04 (up 0.15%); market turnover was 57.56 million rupees. Vidullanka said project companies it holds equity in won bids to install 18.7 MW/93 MWh of BESS, with its estimated equity share about 600 million rupees.
Colombo Stock Exchange opened higher: ASPI up 0.18% (37.48 pts) at 21,104.37 and S&P SL20 up 0.46% at 5,970.10, with turnover Rs 43.59m. Singer Finance set rights-issue and EGM/XR dates; Pan Asia Banking plans to raise up to Rs 5bn via listed debentures opening Oct 1, 2026.
Fitch affirmed Ceat Kelani Holdings' National Long-Term Rating at 'AA+(lka)' with a Stable Outlook. Fitch highlighted CKH's market leadership and resilient finances but warned of near-term margin pressure from higher input and energy costs and import competition, with EBITDA net leverage seen peaking around 0.6x in FY28.
Diabetasol named Kalasuri Channa Wijewardena as brand ambassador for its 'Keep Life in Rhythm' campaign to promote specialised nutrition for people with diabetes. The product is marketed locally by Hemas Pharmaceuticals in partnership with Kalbe.
Hemas Holdings' Baby Cheramy partnered with the Sri Lanka College of Paediatricians at the 19th Asia Pacific Congress of Paediatrics and showcased its relaunched multi‑benefit baby care range. The products are dermatologically/clinically tested and marketed as baby‑safe, with new formulations (Natural Ceramides) and diaper/pants options.
Colombo Stock Exchange closed higher with the ASPI up 0.12% (25.00 pts) at 21,382.74 and the S&P SL20 up 0.19% at 6,015.08, on turnover of 333 million rupees. Galle Face Capital Partners received in-principle CSE approval to list up to 4,060,218 new ordinary shares via a scrip dividend; its shares closed down 2.45% at 19.90 rupees.
Colombo Stock Exchange closed down as the ASPI fell 0.25% (down 53.01 pts) to 21,489.22 on Wednesday, with market turnover at LKR 972.23 mn and capital goods leading turnover at LKR 283.19 mn. HNB Finance appointed four new independent/non-executive directors effective Sept 8, 2026; its shares closed down 1.20% at 8.20 rupees.
Colombo Stock Exchange closed marginally up, ASPI +0.03% at 21,325.64 on Rs1.28bn turnover; banks led turnover. Top contributors included Ceylinco Insurance, Haycarb, Dipped Products and National Development Bank, while Browns Investments, Carson Cumberbatch, Melstacorp and Hemas were laggards; Hunas announced a strategic partnership with Tokyo-based CCH Inc.